Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 4/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | PLAT | P00750 | 2/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24834880 | 0.89 | PLAT (0.36) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL29785416 | 0.89 | PLAT (0.36) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL24834786 | 0.88 | PLAT (0.37) | PLATPDE10A | |
| SCHEMBL29785449 | 0.88 | PLAT (0.34) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL29785486 | 0.88 | ARF6 (0.31) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL24834809 | 0.88 | PLAT (0.34) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL24834778 | 0.88 | ARF6 (0.31) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL24834885 | 0.86 | SLC6A7 (0.36) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL24834859 | 0.86 | PLAT (0.36) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL29785492 | 0.86 | PLAT (0.36) | PLATHSP90AA1GAAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114786778-A | Therapeutic compounds | 基因泰克公司 | 2022-07-22 | — | — | CN | claimed |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4065230-A1 | THERAPEUTIC COMPOUNDS | Genentech, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-114786778-A | Therapeutic compounds | 基因泰克公司 | 2022-07-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | YAP1, YES1, TEAD2 | FASN 3334/4885KDM1A 3188/4885PLAT 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.